Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + lenalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma (Phase II, Korea)
KCT0004005Phase 2Terminated
- Sponsor
- Boryung
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, lenalidomide, dexamethasone in multiple myeloma (MM), sponsored by Boryung. Started Dec 2019; status: terminated.
02
Drugs
bortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0004005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004005.